What is CUP?
Cancer of unknown primary (CUP), which accounts for 3-5% of all cancer diagnoses worldwide, presents a diagnostic challenge due to its undetermined origin, resulting in limited treatment options and a poor prognosis of 6 to 16 months. Site-specific chemotherapy in CUP cases can improve overall survival rates by 15-20% compared to general chemotherapy, underscoring the critical need for accurate diagnosis to expand therapeutic strategies for CUP patients.